We make select early investments at the Seed stage in private biotech ventures as the lead or sole investor and participate in Series-A investments.

Company Formation

We launch and fund de novo companies to advance important innovations, which may otherwise lack the proper resources to progress and thrive.

Beyond financial support, we work with our portfolio companies by providing management support and development expertise through a group of highly experienced advisors and operators. Together with our portfolio companies, we identify critical value inflection milestones and develop a plan to successfully arrive there. By leveraging the Tellus BioVentures team, we help companies operate in an efficient manner, focused on achieving milestones and transforming innovative science into important therapies for patients.



Aegle Therapeutics

developing extracellular vesicle therapy for the treatment of rare diseases, including dystrophic epidermolysis bullosa, and other severe dermatological disorders

Dianthus Therapeutics

discovering and developing monoclonal antibody therapeutics that modulate the immune complement system for the treatment of auto-immune diseases

Interius BioTherapeutics

developing novel methods for in vivo cell-specific gene delivery and creating a breakthrough platform with multi-product potential


advancing a novel ADC therapeutic and targeting tumor-produced factors that suppress humoral immune responses


developing novel therapies for serotonergic driven disorders


expedient development of TB-019, a first-in-class treatment for NASH targeting 4-HNE

Viridian Therapeutics (NASDAQ: VRDN)

most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease

Vittoria Biotherapeutics

delivering next-generation, paradigm-shifting T-cell therapies that address unmet medical needs

Zenas BioPharma

developing and delivering therapies for auto-immune diseases